Royalty Report: Drugs, Cancer, Drug Discovery – Collection: 344540

License Grant

University grants a license under the patent rights to
—  develop, make, have made, use, sell, offer to sell, lease, and import Therapeutic Licensed Products and Diagnostic Licensed Products in the Disease Fields;
—  develop, make, have made, use, sell, offer to sell, lease, and import Reagent Licensed Products; and,
—  develop and perform Licensed Processes, unless earlier terminated per the terms of this Agreement.

For the Limited-Term Option to License Improvements Dominated by Patent –
— Subject to any obligations of University to third parties, University grants an exclusive option to add to the Patent Rights of this Agreement Universitys patent rights in inventions conceived and reduced to practice, before June 1, 2010;
— dominated by the Patent Rights licensed under this Agreement on the Effective Date and,
— arising from research performed solely in the laboratory, and,
— directly related to a Fully funded project as of, or within four (4) months of, Companys being provided a copy of the related invention disclosure form by University.

This agreement is exclusive for Therapeutic and Diagnostic products, but may be exclusive or non-exclusive for the Reagent products.

License Property

University is the owner or joint owner of certain Patent Rights relating to
Non-Linear Hydrophilic-Hydrophobic Biopolymers,
Biodegradable Microparticles and Injectable Nanospheres,
Sub 100Nm Biodegradable Polymer Spheres Capable of Releasing Nucleic Acids,
Targeted Delivery of Nano- or Microparticles Using Nucleic Acid Ligands,
Bioadhesive Polymers-Coated Controlled Release Polymer Particles as Efficient Oral Delivery Vehicles for Biopharmaceuticals,
High Throughput Synthesis of Functionalized Materials,
Method ofldentifying Particles with Desired Characteristics from a Library of Particles,
Formulation of Polymeric Particles for Prostate Cancer Targeting,
Multi-Block Co-Polymer for the Development of Functional Particles,
Nanocrystal-Aptamer-Doxorubicin Multifunctional Conjugate System for Cancer Diagnosis and Treatment,
Method of isolating Nucleic Acid Ligands that are Taken up by Cells and Uses Thereof,
Affibodies as a Targeting Ligand in Controlled Drug Delivery Systems,
Receptor Triggered Controlled Drug Delivery Systems to Cross,
Endothelial and/or Epithelial Cell Layers and their Method of Preparation,
Reverse Micelle Nanoprecipitation A Method for Encapsulating Nucleic Acids in Biodegradable Polymers, and, Amphiphilic Compound Assisted Polymeric Particles for Targeted Delivery.

Licensed Products shall mean Reagent, Therapeutic and Diagnostic Licensed Products.

Reagent Licensed Product shall mean any product used primarily as a reagent for research or other non-therapeutic and non-diagnostic purpose that, in whole or in part
– absent the license granted hereunder, would infringe one or more claims of the Patent Rights; or
– is manufactured by using a Licensed Process or that, when used, practices a Licensed Process.

Therapeutic Licensed Product shall mean any therapeutic product except therapeutic or prophylactic vaccines (which are specifically excluded from the definition of Therapeutic Licensed Product), used for a therapeutic purpose that, in whole or in part
– absent the license granted hereunder, would infringe one or more claims of the Patent Rights; or
– is manufactured by using a Licensed Process or that, when used, practices a Licensed Process.

Diagnostic Licensed Product shall mean any product used for a diagnostic purpose that, in whole or in part
– absent the license granted hereunder, would infringe one or more claims of the Patent Rights; or
– is manufactured by using a Licensed Process or that, when used, practices a Licensed Process.

Field of Use

Disease Field shall mean a field specific to a class of diseases. Examples include, but are not limited to cancer;  cardiovascular disease (atherosclerosis, congestive heart failure, etc.); immune/inflammatory disorders (rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, etc.); respiratory diseases (asthma, emphysema, central obstructive pulmonary disease, etc.); central nervous system disorders (Alzheimers disease, Parkinsons, etc.); and metabolic diseases (obesity, diabetes, etc.).

License Grant

In the original agreement, therapeutic and prophylactic vaccines were specifically excluded from the definition of Therapeutic Licensed Product under the License Agreement.

For clarification, the University has the right to grant exclusive licenses to third parties under the Patent Rights to develop, make, have made, use, sell, offer to sell, lease, and import any product that is solely a therapeutic or prophylactic vaccine and to develop and perform Licensed Processes solely to develop, make, have made, use, sell, offer to sell, lease and import any product that is solely a therapeutic or prophylactic vaccine.

License Grants, of the License Agreement shall be amended to read in its entirety as follows
The University grants to Company a license under the Patent Rights to develop, make, have made, use, sell, offer to sell, lease, and import Therapeutic Licensed Products and Diagnostic Licensed Products  in the Disease Field; develop, make, have made, use, sell, offer to sell, lease, and import Reagent Licensed Products; and develop and perform Licensed Processes except, solely, to develop, make, have made, use, sell, offer to sell, lease, and import any product that is solely a therapeutic or prophylactic vaccine, unless earlier terminated per the terms of this Agreement.

In order to establish an exclusive period for Company and University agrees that it shall not grant any other license under the Patent Rights (except University Sub 100Nm Biodegradable Polymer Spheres Capable Of Releasing Nucleic Acids) to develop, make, have made, use, sell, offer to sell, lease or import Therapeutic Licensed Products or Diagnostic Licensed Products in the Disease Fields in the Territory during the Term, or to develop or perform Licensed Processes, other than solely to develop, make, have made, use, sell, offer to sell, lease, or import any product that is solely a therapeutic or prophylactic vaccine, in the Disease Fields in the Territory during the Term, unless earlier terminated per the terms of this Agreement.

License Property

University is the owner or joint owner of certain Patent Rights relating to Formulation of Polymeric Particles for Prostate Cancer Targeting, and, Cancer Cell Targeting Using Nanoparticles.

Field of Use

The original agreement states Disease Field shall mean a field specific to a class of diseases. Examples include, but are not limited to cancer;  cardiovascular disease (atherosclerosis, congestive heart failure, etc.); immune/inflammatory disorders (rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, etc.); respiratory diseases (asthma, emphysema, central obstructive pulmonary disease, etc.); central nervous system disorders (Alzheimers disease, Parkinsons, etc.); and metabolic diseases (obesity, diabetes, etc.).

License Grant

Included in a license patent agreement, the University agrees that the Company may grant sublicense solely to a Third Party.  The Licensee has granted a sublicense.

License Property

University is the owner or joint owner of certain Patent Rights relating to Formulation of Polymeric Particles for Prostate Cancer Targeting, and, Cancer Cell Targeting Using Nanoparticles.

Field of Use

The original agreement states Disease Field shall mean a field specific to a class of diseases. Examples include, but are not limited to cancer;  cardiovascular disease (atherosclerosis, congestive heart failure, etc. ); immune/inflammatory disorders (rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, etc.); respiratory diseases (asthma, emphysema, central obstructive pulmonary disease, etc.); central nervous system disorders (Alzheimers disease, Parkinsons, etc.); and metabolic diseases (obesity, diabetes, etc.).

License Grant

The University grants an exclusive license, under the Licensed Patents, with the right to sublicense through multiple tiers, to make, have made, use, have used, offer for sale, have offered for sale, sell, have sold, import, have imported, export or have exported Licensed Products, and to practice any Licensed Method, within the Field in the Licensed Territory.

License Property

The University has produced inventions pertaining to drug delivery using targeted nanoparticles OCR 1670 and 3070.

The Patents are for Methods of Treatment with Drug Loaded Polymeric Materials.

Field of Use

The Field shall mean the use of Licensed Products containing a polymer and a therapeutic agent for the treatment of cancer. The Field shall specifically exclude the use of Licensed Products for the treatment of brain cancer; for therapeutic or prophylactic cancer vaccines, including where such vaccines incorporate an adjuvant but not an antigen; and for therapeutic or prophylactic vaccines for infectious diseases or allergies.

License Grant

University grants to Company a nonexclusive, worldwide license, without the right to sublicense, in the Patent Rights to make, have made, use, offer to sell, sell, have sold and imported Licensed Products in the Field, including research for development of Licensed Products.

License Property

The University intellectual property rights relate to therapeutic applications of RNAi, entitled Methods of Synthesis and Formulation of New Reagents for Efficient Nucleic Acids Delivery in Cells and Animals, and,  Microwave Assisted Method of Synthesis of New Cationic Reagents for Efficient Drug Delivery in Cells and Animals.

Field of Use

The Field means Primary Field and Secondary Field collectively. Any commercial sale of research reagents covered by the Patent Rights is specifically excluded from the Field.

Primary Field means therapeutic, prophylactic, or diagnostic health care applications for amyotrophic lateral sclerosis (ALS), diabetes, and obesity, in humans.

Secondary Field means therapeutic, prophylactic, or diagnostic health care applications in humans that are not included in the Primary Field.

License Grant

University grants to Company an exclusive, worldwide license in the Patent Rights to make, have made, use, offer to sell, sell, have sold and imported Licensed Products in the Field, including research for development of Licensed Products.

License Property

University owns intellectual property rights which relate to therapeutic applications of RNAi, as described in University’s invention Methods of Efficient siRNA Delivery in Human Cells — New Approaches for the Development of siRNA Therapeutics; and,  Design, Synthesis, and Formulation of Nanotransporters for Efficient Nucleic Acids and other Pharmaceutics Delivery in Cells and Animals; and, Therapeutic Silencing of Genes Involved in Cholesterol Biosynthesis and Other Metabolic Disorders by Chemically Modified siRNA and New Delivery Agents.

Field of Use

The Field means Primary Field and Secondary Field collectively. Any commercial sale of research reagents covered by the Patent Rights is specifically excluded from the Field.

Primary Field means therapeutic, prophylactic, or diagnostic health care applications for amyotrophic lateral sclerosis (ALS), diabetes, and obesity, in humans.

Secondary Field means therapeutic, prophylactic, or diagnostic health care applications in humans that are not included in the Primary Field.